AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19474132
Drug: Skim milk
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skim milk (600 mL; 25 g protein, 36 g lactose, <1 g fat; 1062 kJ)
Trial: 19474132
Drug: Fruit drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit drink (600 mL; <1 g protein, 63 g sugar, <1 g fat; approximately 1062 kJ)
Trial: 28560658
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 10 mg
Trial: 14975536
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T elevation (>0.1 microg/l)
Trial: 14975536
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T results (>0.1 vs. < or =0.1 microg/l)
Trial: 7950335
Drug: 0.5g imipenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5g imipenem infusion
Trial: 7950335
Drug: 1g imipenem
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1g imipenem infusion
Trial: 31813637
Drug: Ixekizumab Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q4W (80 mg every 4 weeks)
Trial: 31813637
Drug: Ixekizumab Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q2W (80 mg every 2 weeks)
Trial: 28114846
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg progesterone pessaries, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Trial: 28114846
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Trial: 28114846
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg progesterone pessaries
Trial: 26643116
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days high dose primaquine
Trial: 26643116
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days high dose primaquine
Trial: 26643116
Drug: Weekly primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly primaquine doses for 8 weeks (for G6PD deficient patients)
Trial: 20736505
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for at least 2 weeks
Trial: 20736505
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg once daily for at least 2 weeks
Trial: 20736505
Drug: Post-treatment comparison
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment comparison between omeprazole and rabeprazole groups
Trial: 15886723
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day racemic fluoxetine
Trial: 15886723
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day R-fluoxetine
Trial: 15886723
Drug: 120 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day R-fluoxetine
Trial: 12818939
Drug: Rofecoxib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (1 mg/kg)
Trial: 10912700
Drug: Gentamicin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin therapy administered transtympanically
Trial: 6366725
Drug: T4 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T4 therapy
Trial: 31574237
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment in patients aged ≥50 years
Trial: 30212948
Drug: Rational Emotive
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational Emotive Behavior Therapy (REBT) intervention for 12 weeks and a follow-up program for 2 weeks
Trial: 27465076
Drug: Intragastric balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric balloon (IGB) therapy
Trial: 22038680
Drug: Rectal balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal balloon training (RBT) with pelvic floor muscle training (PFMT)
Trial: 19852282
Drug: Shengjing Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengjing Capsule at a dose of 1.6 g tid for 12 weeks
Trial: 19852282
Drug: Vit E
RxNorm normalized name: tocopherol (vit E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit E at 50 mg tid for 12 weeks
Trial: 10519449
Drug: Gasec-40 Gastrocaps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gasec-40 Gastrocaps (40 mg daily for 5 days)
Trial: 10519449
Drug: Antra 40
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antra 40 (40 mg daily for 5 days)
Trial: 7500507
Drug: Step II
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step II Diet and lovastatin (40 mg daily) plus colestipol (30 g daily)
Trial: 1789528
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 or 20 mg once a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Trial: 1789528
Drug: Bezafibrate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (600 mg 3 times a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Trial: 30715997
Drug: Buparlisib 100
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 1)
Trial: 30715997
Drug: Buparlisib 100
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 2)
Trial: 30715997
Drug: Buparlisib 100
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib 100 mg once daily on a continuous 28-day schedule
Trial: 29488430
Drug: Optimized dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized dose of PPI (Control)
Trial: 19602758
Drug: Oral drotaverine
RxNorm normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drotaverine (80 mg) plus mefenamic acid (250 mg)
Trial: 19602758
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with diazepam
Trial: 19602758
Drug: Oral drotaverine
RxNorm normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drotaverine plus mefenamic acid
Trial: 17785361
Drug: Supraphysiological GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiological GH therapy
Trial: 15189751
Drug: TLA 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLA 0.5% solution once daily
Trial: 15189751
Drug: TIM 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIM 0.5% ophthalmic solution twice daily
Trial: 7905369
Drug: Propafenone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone plus quinidine sulfate (60 mg orally every 8 hours)
Trial: 2577015
Drug: Nifedipine sublingual
RxNorm normalized name: nifedipine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine sublingual 10-20 mg alone (group I, n = 19)
Trial: 2577015
Drug: Nifedipine sublingual
RxNorm normalized name: nifedipine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine sublingual 10-20 mg associated with furosemide and clonidine (group II, n = 29)
Trial: 186089
Drug: Thymoxamine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoxamine (150 mg i.v.)
Trial: 31218354
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg b.i.d.
Trial: 23085743
Drug: Daptomycin 4
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 4 mg/kg once daily for 7-14 days
Trial: 23085743
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g twice daily for 7-14 days
Trial: 18470565
Drug: 0.2 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 percent glyceryl trinitrate suppository (n = 21)
Trial: 16482475
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of WBV and squat (S+V)
Trial: 3313041
Drug: Gemfibrozil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (600 mg twice daily)
Trial: 8103616
Drug: 300 mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/daily ranitidine
Trial: 8103616
Drug: 40 mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/daily famotidine
Trial: 8103616
Drug: 300 mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/daily nizatidine
Trial: 8103616
Drug: 40 mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/daily omeprazole
Trial: 26151620
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (32 IU)
Trial: 14994771
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin (oral)
Trial: 9488244
Drug: CS-866 10
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-866 10 mg
Trial: 9488244
Drug: CS-866 20
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-866 20 mg
Trial: 9488244
Drug: CS-866 80
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-866 80 mg
Trial: 9488244
Drug: CS-866 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-866 (all doses above 5 mg)
Trial: 9488244
Drug: CS-866 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-866 (2.5 to 10 mg and 5 to 20 mg)
Trial: 8957583
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily
Trial: 8452167
Drug: Ceftazidime 0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 0.5-2 g three times a day or 1-2 g twice a day
Trial: 3085738
Drug: Sodium Valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Valproate (SV) 800 mg
Trial: 27508937
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (ICBT) in addition to care as usual (CAU), n = 65
Trial: 22632734
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D(3) supplementation 1600 IU (40 μg) per day
Trial: 20420759
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (HFM) (50 g fat)
Trial: 20420759
Drug: Low-fat, high-carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-carbohydrate meal (HCM) (5 g fat)
Trial: 11115412
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg daily for 4 weeks)
Trial: 9117878
Drug: RV16 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV16 treatment (0.5-2.9 x 10(4) TCID50)
Trial: 9117878
Drug: RV16 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV16 treatment
Trial: 30376095
Drug: 1 IPV
RxNorm normalized name: IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 IPV at 8 weeks followed by 2 doses of bOPV
Trial: 30376095
Drug: Second IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second IPV dose at 16 weeks
Trial: 30376095
Drug: Sequential IPV-bOPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential IPV-bOPV
Trial: 24711637
Drug: Biocompatible PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible PD solution
Trial: 21262565
Drug: Aripiprazole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (up to 15 mg/day)
Trial: 15781762
Drug: Desloratadine, 5
RxNorm normalized name: Desloratadine, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine, 5 mg/d
Trial: 17165277
Drug: Levocetirizine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine, 5 mg/d
Trial: 17165277
Drug: Montelukast, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, 5 mg/d
Trial: 17165277
Drug: Montelukast +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast + Antihistamine (Desloratadine or Levocetirizine)
Trial: 17165277
Drug: Montelukast +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast + Antihistamine
Trial: 10892625
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical stimulation (FES) therapy, 6 hours/day for 6 weeks, targeting supraspinatus and posterior deltoid muscles.
Trial: 1356519
Drug: Ebrotidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine (800 mg)
Trial: 30945430
Drug: Moisturizer containing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese (experimental cream)
Trial: 30945430
Drug: 0.02% Triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% Triamcinolone acetonide cream (TA cream)
Trial: 26859481
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - no supplement
Trial: 24863949
Drug: Vildagliptin-metformin combination
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin-metformin combination regimen
Trial: 24863949
Drug: Standard-of-care metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care metformin monotherapy
Trial: 22175269
Drug: Prescription review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription review sent to physician
Trial: 22175269
Drug: Prescription review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription review sent to physician and current comprehensive medication record sent to the patient
Trial: 18418965
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (WM) group treated with aspirin, Clopidogrel, statins
Trial: 18418965
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) group treated with Dahuang Zhechong Pill, Tianma Duzhong Capsule, and self‐formulated decoctions
Trial: 18418965
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine (IM) group treated with both TCM and WM
Trial: 14606705
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg Talpha1 (low dose group; n = 8)
Trial: 14606705
Drug: 1.6 mg
RxNorm normalized name: menthol 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg Talpha1 (high dose group; n = 8)
Trial: 8894384
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support system for oral hypoglycaemic therapy
Trial: 30021449
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (IG)
Trial: 30021449
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (DG)
Trial: 30021449
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of early treatment
Trial: 27287084
Drug: LNG/EE extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE extended regimen (84 days of LNG 150 μg/EE 30 μg with 7 days of EE 10 μg)
Trial: 27287084
Drug: LNG/EE 21/7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE 21/7 (21 days of LNG 100 μg/EE 20 μg with 7 days of placebo)
Trial: 17262225
Drug: Categories of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Categories of assessment for esthetic evaluation, functional assessment, biological responses to restorative materials
Trial: 14973528
Drug: Colchicine 0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5-2.5 mg daily for 4 months
Trial: 11245843
Drug: Target merging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target merging (merging pairs of items, e.g., connecting item locations with a line segment or drawing the convex hull)
Trial: 9840855
Drug: Ultrasound (US)
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US) guidance with 20 mL 0.5% bupivacaine
Trial: 9840855
Drug: Nerve stimulator
RxNorm normalized name: nerve stimulator device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulator (NS) guidance with 20 mL 0.5% bupivacaine
Trial: 9840855
Drug: Nerve stimulator
RxNorm normalized name: nerve stimulator device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulator (NS) guidance with 30 mL 0.5% bupivacaine
Trial: 2510959
Drug: Urokinase therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase therapy (two weeks administration)
Trial: 2510959
Drug: Urokinase therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase therapy (consecutive administration)
Trial: 2510959
Drug: Antiplatelet drugs
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drugs (control)
Trial: 26353947
Drug: Non-metformin antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-metformin antidiabetic medications
Trial: 26353947
Drug: No antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antidiabetic medication
Trial: 2254723
Drug: Intensified conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified conventional treatment (ICT, n = 44)
Trial: 2254723
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (RT, n = 53)
Trial: 6402199
Drug: Dihydrocodeine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine 15 mg
Trial: 29325486
Drug: Intensive client-centred
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive client-centred occupational therapy (ICC-OT) - maximum 22 sessions
Trial: 29325486
Drug: Usual practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual practice - maximum 3 sessions of occupational therapy
Trial: 31159805
Drug: Structured information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured information delivery, personalised written physical activity prescription (number of steps per day), pedometer, and pedometer logbook.
Trial: 31159805
Drug: Structured information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured information delivery, personalised written physical activity prescription, pedometer, and pedometer logbook.
Trial: 18278978
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion SR 150 mg/day
Trial: 17099376
Drug: Intravenous cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefuroxime 750 mg just before the procedure followed by two further doses every 8 h (Group A)
Trial: 17099376
Drug: Single application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of povidone-iodine (Betadine) antiseptic spray (Group B)
Trial: 17099376
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cefuroxime and Betadine spray (Group C)
Trial: 12958051
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus O2
Trial: 9308557
Drug: Prilocaine-lidocaine patch
RxNorm normalized name: lidocaine / prilocaine Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine-lidocaine patch (anesthetic patch)
Trial: 8346498
Drug: Nicotine (0.08‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.08‐2.0 mg)